Updates in HER2+ Early and Metastatic Breast Cancer : Episode 1

Incidence and Typical Prognosis of HER2+ Early Breast Cancer

Jan 20, 2023

Joyce O’Shaughnessy, MD
Virginia Borges, MD

Virginia Borges, MD, explains how common HER2+ early breast cancer is and the goals of treatment for patients.

EP: 1.Incidence and Typical Prognosis of HER2+ Early Breast Cancer

EP: 2.Neoadjuvant Treatment of HER2+ Early Breast Cancer

Related Videos

Related Content

WHO Outlines New Framework for Early Detection and Management of Breast Cancer

February 3rd 2023

Nair Notes the Benefits of Yoga as a Complementary Therapy in Nonmetastatic Breast Cancer

January 30th 2023

Breast Cancer Expert Focuses on Decoding Biomarkers

February 2nd 2023

Goetz and Choong Describe the Need for Adjuvant Endocrine Therapy in ER-positive Breast Cancer

January 23rd 2023

Further Study and Tailored Treatments Remain Unmet Needs in Male Breast Cancer

January 30th 2023

FDA Approves Elacestrant for ER+/HER2–, ESR1-Mutated Advanced or Metastatic Breast Cancer

January 27th 2023

WHO Outlines New Framework for Early Detection and Management of Breast Cancer

February 3rd 2023

Nair Notes the Benefits of Yoga as a Complementary Therapy in Nonmetastatic Breast Cancer

January 30th 2023

Breast Cancer Expert Focuses on Decoding Biomarkers

February 2nd 2023

Goetz and Choong Describe the Need for Adjuvant Endocrine Therapy in ER-positive Breast Cancer

January 23rd 2023

Further Study and Tailored Treatments Remain Unmet Needs in Male Breast Cancer

January 30th 2023

FDA Approves Elacestrant for ER+/HER2–, ESR1-Mutated Advanced or Metastatic Breast Cancer

January 27th 2023

WHO Outlines New Framework for Early Detection and Management of Breast Cancer

February 3rd 2023

Nair Notes the Benefits of Yoga as a Complementary Therapy in Nonmetastatic Breast Cancer

January 30th 2023

Breast Cancer Expert Focuses on Decoding Biomarkers

February 2nd 2023

Goetz and Choong Describe the Need for Adjuvant Endocrine Therapy in ER-positive Breast Cancer

January 23rd 2023

Further Study and Tailored Treatments Remain Unmet Needs in Male Breast Cancer

January 30th 2023

FDA Approves Elacestrant for ER+/HER2–, ESR1-Mutated Advanced or Metastatic Breast Cancer

January 27th 2023

Related Content

WHO Outlines New Framework for Early Detection and Management of Breast Cancer

February 3rd 2023

Nair Notes the Benefits of Yoga as a Complementary Therapy in Nonmetastatic Breast Cancer

January 30th 2023

Breast Cancer Expert Focuses on Decoding Biomarkers

February 2nd 2023

Goetz and Choong Describe the Need for Adjuvant Endocrine Therapy in ER-positive Breast Cancer

January 23rd 2023

Further Study and Tailored Treatments Remain Unmet Needs in Male Breast Cancer

January 30th 2023

FDA Approves Elacestrant for ER+/HER2–, ESR1-Mutated Advanced or Metastatic Breast Cancer

January 27th 2023

Editorial Board

CancerNetwork.com

OncNursingNews.com

TargetedOnc.com

Terms & Conditions

Do Not Sell My Information

Contact Info

2 Clarke Drive
Cranbury, NJ 08512

© 2023 MJH Life Sciences

All rights reserved.